Blue Cross and Blue Shield of Texas policies, page 9

Search Blue Cross and Blue Shield of Texas's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

543 public policies Substrate tracks for Blue Cross and Blue Shield of Texas, by title.

Blue Cross and Blue Shield of Texas policies
PolicyDetailsCodesSource
Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to IschemiaSUR703.027 · Commercial, Medicaid7Original policy ↗
ProlotherapyMED201.013 · Effective Jun 15, 2025 · Commercial, Medicaid5Original policy ↗
Prostate Artery Embolization for Benign Prostatic HyperplasiaSUR710.027 · Commercial, Medicaid1Original policy ↗
Prostate Biopsies Specimen AnalysisCPCPLAB005 · Effective Jan 3, 2026 · Commercial, Medicaid · TX2Original policy ↗
Prostate Specific Antigen (PSA) TestingRPLAB006 · Effective Sep 4, 2026 · Commercial, Medicaid · TX4Original policy ↗
Prostatic Urethral LiftSUR710.023 · Effective Oct 15, 2025 · Commercial, Medicaid4Original policy ↗
Provider characteristic codes for medication-assisted treatmentCommercial, Medicaid · TX—Original policy ↗
Psychiatry/Psychotherapy Services - Professional ProviderCPCP051 · Effective Dec 22, 2025 · Commercial, Medicaid · TX35Original policy ↗
Psychological and Neuropsychological TestingCPCP008 · Effective Mar 2, 2026 · Commercial, Medicaid · TX17Original policy ↗
Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder, Cognitive Impairment, or Autism Spectrum DisorderMED205.040 · Commercial, Medicaid6Original policy ↗
Quantitative Sensory TestingMED205.030 · Commercial, Medicaid6Original policy ↗
Radioembolization for Primary and Metastatic Tumors of the LiverRAD601.047 · Commercial, Medicaid7Original policy ↗
Radiofrequency Ablation (RFA) of Primary or Metastatic Liver TumorsSUR709.029 · Effective Jan 1, 2026 · Commercial, Medicaid4Original policy ↗
Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver TumorsSUR701.021 · Effective Dec 1, 2025 · Commercial, Medicaid12Original policy ↗
Radiofrequency Energy Therapy for Stress Urinary IncontinenceSUR710.021 · Commercial, Medicaid3Original policy ↗
Radiofrequency Volumetric Tissue Reduction for Nasal ObstructionSUR706.001 · Effective Sep 1, 2026 · Commercial, Medicaid1Original policy ↗
Ravulizumab-cwvzRX501.107 · Commercial, Medicaid1Original policy ↗
Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic ConditionsRX501.034 · Effective Apr 15, 2026 · Commercial, Medicaid6Original policy ↗
Reconstructive Breast SurgerySUR716.011 · Commercial, Medicaid38Original policy ↗
Reconstructive Breast Surgery/Management of Breast ImplantsSUR716.009 · Commercial, Medicaid10Original policy ↗
Reduction Mammaplasty for Breast-Related SymptomsSUR716.012 · Commercial, Medicaid1Original policy ↗
RemdesivirRX501.130 · Commercial, Medicaid1Original policy ↗
Remote Electrical Neuromodulation for MigrainesSUR701.046 · Commercial, Medicaid2Original policy ↗
Renal Denervation for Uncontrolled HypertensionSUR701.030 · Effective Oct 15, 2025 · Commercial, Medicaid4Original policy ↗
Reproductive Techniques and Immunotherapy for Recurrent Fetal LossOB402.023 · Commercial, Medicaid49Original policy ↗
ReslizumabRX501.083 · Commercial, Medicaid1Original policy ↗
Responsive Neurostimulation for the Treatment of Refractory Focal EpilepsySUR712.039 · Effective Dec 1, 2025 · Commercial, Medicaid18Original policy ↗
Revakinagene taroretcel-lweyRX501.185 · Commercial, Medicaid1Original policy ↗
Revenue Codes Requiring Supporting CPT, HCPCS and/or NDC Codes - Outpatient Facility ClaimsRP018 · Effective Aug 28, 2026 · Commercial, Medicaid · TX—Original policy ↗
Rhinomanometry, Acoustic Rhinometry, Optical Rhinometry and Acoustic PharyngometryMED204.004 · Commercial, Medicaid3Original policy ↗
Risankizumab-rzaaRX501.147 · Commercial, Medicaid1Original policy ↗
Rituximab and Biosimilars for Non-Oncologic IndicationsRX502.030 · Effective Jan 1, 2026 · Commercial, Medicaid5Original policy ↗
Robotic Assisted SurgeryRP052 · Effective Nov 16, 2026 · Commercial, Medicaid · TX7Original policy ↗
RomiplostimRX501.157 · Commercial, Medicaid2Original policy ↗
Romosozumab-aqqgRX501.159 · Commercial, Medicaid1Original policy ↗
Rozanolixixumab-noliRX501.161 · Effective Dec 15, 2025 · Commercial, Medicaid1Original policy ↗
Sacral Nerve Neuromodulation/StimulationSUR710.018 · Commercial, Medicaid21Original policy ↗
Sacroiliac Joint InjectionsSUR705.043 · Effective Jan 1, 2026 · Commercial, Medicaid3Original policy ↗
Salivary Hormone TestingRPLAB034 · Effective Sep 4, 2026 · Commercial, Medicaid · TX17Original policy ↗
SARS-CoV-2 (COVID-19) Antibody TestingMED207.162 · Commercial, Medicaid8Original policy ↗
Saturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer, Including Comprehensive 3D Mapping with BiopsySUR717.015 · Commercial, Medicaid5Original policy ↗
Scleral ShellDME104.003 · Commercial, Medicaid3Original policy ↗
Seat Lift Mechanisms and Patient LiftsDME101.034 · Commercial, Medicaid16Original policy ↗
SecukinumabRX501.169 · Effective Jun 15, 2026 · Commercial, Medicaid1Original policy ↗
Sensory Integration Therapy and Auditory Integration TherapyTHE803.020 · Effective Sep 15, 2026 · Commercial, Medicaid1Original policy ↗
Sepsis PolicyCPCP041 · Effective Apr 30, 2026 · Commercial, Medicaid · TX—Original policy ↗
Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue DiseasesMED207.159 · Commercial, Medicaid20Original policy ↗
Serum Tumor Markers for MalignanciesRPLAB037 · Effective Sep 4, 2026 · Commercial, Medicaid · TX60Original policy ↗
Sexual Dysfunctions, Assessment and TreatmentMED201.030 · Commercial, Medicaid64Original policy ↗
Shoulder ResurfacingSUR705.032 · Commercial, Medicaid3Original policy ↗

Back to Blue Cross and Blue Shield of Texas · Blue Cross and Blue Shield of Texas prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.